ProPhase Labs, Inc. (NASDAQ: PRPH) Stock Competitors & Peer Comparison
See PRPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRPH | $0.02 | -17.67% | 346.2K | -0.01 | -$3.01 | N/A |
| RPRX | $61.31 | +1.21% | 27.2B | 11.68 | $5.25 | +1.50% |
| CORT | $122.25 | +2.71% | 13.1B | 345.86 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $68.62 | -3.42% | 6.1B | 490.14 | $0.14 | N/A |
| KNSA | $79.03 | +0.71% | 6B | 87.81 | $0.90 | N/A |
| PBH | $51.31 | +1.56% | 2.4B | 11.61 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $22.37 | +4.53% | 1.3B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
PRPH vs RPRX Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while RPRX trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas RPRX's P/E ratio is 11.68. In terms of profitability, PRPH's ROE is -13.59%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, PRPH is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
PRPH vs CORT Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CORT has a market cap of 13.1B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CORT trades at $122.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CORT's P/E ratio is 345.86. In terms of profitability, PRPH's ROE is -13.59%, compared to CORT's ROE of +0.08%. Regarding short-term risk, PRPH is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
PRPH vs WBA Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas WBA's P/E ratio is -1.64. In terms of profitability, PRPH's ROE is -13.59%, compared to WBA's ROE of -0.42%. Regarding short-term risk, PRPH is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
PRPH vs LQDA Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while LQDA trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas LQDA's P/E ratio is 490.14. In terms of profitability, PRPH's ROE is -13.59%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, PRPH is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
PRPH vs KNSA Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while KNSA trades at $79.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas KNSA's P/E ratio is 87.81. In terms of profitability, PRPH's ROE is -13.59%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, PRPH is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
PRPH vs PBH Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while PBH trades at $51.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas PBH's P/E ratio is 11.61. In terms of profitability, PRPH's ROE is -13.59%, compared to PBH's ROE of +0.09%. Regarding short-term risk, PRPH is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
PRPH vs HROWL Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas HROWL's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, PRPH is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
PRPH vs LTGO Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while LTGO trades at $22.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas LTGO's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to LTGO's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
PRPH vs HROWM Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas HROWM's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, PRPH is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
PRPH vs HELP Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while HELP trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas HELP's P/E ratio is -3.02. In terms of profitability, PRPH's ROE is -13.59%, compared to HELP's ROE of -0.71%. Regarding short-term risk, PRPH is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
PRPH vs SVA Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas SVA's P/E ratio is -5.68. In terms of profitability, PRPH's ROE is -13.59%, compared to SVA's ROE of -0.01%. Regarding short-term risk, PRPH is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
PRPH vs CUVL Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CUVL has a market cap of 390.3M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CUVL trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CUVL's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to CUVL's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
PRPH vs HITI Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while HITI trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas HITI's P/E ratio is 61.25. In terms of profitability, PRPH's ROE is -13.59%, compared to HITI's ROE of -0.43%. Regarding short-term risk, PRPH is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
PRPH vs CELG-RI Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, PRPH is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check CELG-RI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
PRPH vs ATLN Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas ATLN's P/E ratio is -0.68. In terms of profitability, PRPH's ROE is -13.59%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, PRPH is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
PRPH vs CTOR Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CTOR's P/E ratio is -1.62. In terms of profitability, PRPH's ROE is -13.59%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, PRPH is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
PRPH vs SDEV Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while SDEV trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas SDEV's P/E ratio is -0.20. In terms of profitability, PRPH's ROE is -13.59%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, PRPH is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
PRPH vs RAD Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas RAD's P/E ratio is -0.05. In terms of profitability, PRPH's ROE is -13.59%, compared to RAD's ROE of +2.76%. Regarding short-term risk, PRPH is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
PRPH vs GLTO Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas GLTO's P/E ratio is -1.78. In terms of profitability, PRPH's ROE is -13.59%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, PRPH is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
PRPH vs NSRX Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while NSRX trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas NSRX's P/E ratio is -5.56. In terms of profitability, PRPH's ROE is -13.59%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, PRPH is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
PRPH vs SCYX Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while SCYX trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas SCYX's P/E ratio is -1.49. In terms of profitability, PRPH's ROE is -13.59%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, PRPH is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SCYX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
PRPH vs CNSY Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CNSY trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CNSY's P/E ratio is -0.42. In terms of profitability, PRPH's ROE is -13.59%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, PRPH is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
PRPH vs BFRI Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while BFRI trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas BFRI's P/E ratio is -2.69. In terms of profitability, PRPH's ROE is -13.59%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, PRPH is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BFRI's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
PRPH vs BFRIW Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, PRPH's ROE is -13.59%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, PRPH is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
PRPH vs COSM Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas COSM's P/E ratio is -0.29. In terms of profitability, PRPH's ROE is -13.59%, compared to COSM's ROE of -1.19%. Regarding short-term risk, PRPH is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
PRPH vs CJJD Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CJJD's P/E ratio is -0.46. In terms of profitability, PRPH's ROE is -13.59%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, PRPH is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
PRPH vs SSY Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas SSY's P/E ratio is -2.86. In terms of profitability, PRPH's ROE is -13.59%, compared to SSY's ROE of -0.09%. Regarding short-term risk, PRPH is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
PRPH vs POM Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas POM's P/E ratio is -0.19. In terms of profitability, PRPH's ROE is -13.59%, compared to POM's ROE of +0.16%. Regarding short-term risk, PRPH is more volatile compared to POM. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
PRPH vs BGMS Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while BGMS trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas BGMS's P/E ratio is -0.25. In terms of profitability, PRPH's ROE is -13.59%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, PRPH is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
PRPH vs PAVS Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while PAVS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas PAVS's P/E ratio is -0.06. In terms of profitability, PRPH's ROE is -13.59%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, PRPH is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
PRPH vs MDVL Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas MDVL's P/E ratio is -0.05. In terms of profitability, PRPH's ROE is -13.59%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, PRPH is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
PRPH vs ATNFW Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas ATNFW's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, PRPH is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
PRPH vs BGMSP Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, PRPH's ROE is -13.59%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, PRPH is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
PRPH vs AZNH Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas AZNH's P/E ratio is 38.35. In terms of profitability, PRPH's ROE is -13.59%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, PRPH is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
PRPH vs LFLYW Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, PRPH's ROE is -13.59%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, PRPH is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LFLYW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
PRPH vs ESRX Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, ESRX has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas ESRX's P/E ratio is 10.69. In terms of profitability, PRPH's ROE is -13.59%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, PRPH is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check ESRX's competition here
Shire plc (NASDAQ: SHPG)
PRPH vs SHPG Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, SHPG has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas SHPG's P/E ratio is 11.35. In terms of profitability, PRPH's ROE is -13.59%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, PRPH is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
PRPH vs OREX Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, OREX has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas OREX's P/E ratio is -0.14. In terms of profitability, PRPH's ROE is -13.59%, compared to OREX's ROE of -0.54%. Regarding short-term risk, PRPH is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
PRPH vs IPXL Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, IPXL has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas IPXL's P/E ratio is -10.11. In terms of profitability, PRPH's ROE is -13.59%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, PRPH is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check IPXL's competition here
POZEN Inc. (NASDAQ: POZN)
PRPH vs POZN Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, POZN has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas POZN's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to POZN's ROE of +0.61%. Regarding short-term risk, PRPH is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
PRPH vs CPD Comparison August 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 346.2K. In comparison, CPD has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.02 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of -0.01, whereas CPD's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to CPD's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CPD's competition here